Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057880	2022-04-01	2022-03-20	A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder	A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder	Neuromyelitis optica spectrum disorder	Case group:Orelabrutinib, orally, 50 mg QD;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Case group:23;	Phase 1	China
2	NCT05284175 (ClinicalTrials.gov)	April 2022	9/3/2022	A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder	A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder	Neuromyelitis Optica Spectrum Disorder	Drug: Orelabrutinib	Peking Union Medical College Hospital	Beijing InnoCare Pharma Tech Co., Ltd.;GCP ClinPlus Co., Ltd.	Not yet recruiting	18 Years	75 Years	All	23	N/A	China
3	NCT04711148 (ClinicalTrials.gov)	March 1, 2021	8/1/2021	A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity	Relapsing Remitting Multiple Sclerosis	Other: placebo;Drug: orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Active, not recruiting	18 Years	55 Years	All	160	Phase 2	United States;China;Poland;Ukraine